Entera Bio Ltd. (ENTX) · Oct 27, 2026 · Exec change

Entera Bio board adds Organon R&D chief as Phase 3 nears

Board appointment — 20+ years of global clinical development experience

Entera Bio’s board appointment adds late-stage development and regulatory expertise as the company prepares EB613 for Phase 3.

Entera is a clinical-stage biotech moving its lead osteoporosis drug, EB613, toward a Phase 3 registrational program while advancing EB612 toward an initial clinical study; recent financing was intended to fund that plan into 2030. The appointment adds relevant execution experience at the right point in the pipeline. Juan Camilo Arjona Ferreira joins the board effective December 1, 2026, replacing Haya Taitel. His background spans late-stage development, regulatory affairs, women’s health and senior pharmaceutical leadership, including his current role as Organon’s Head of Research & Development and Chief Medical Officer. 〔0〕 That is directly relevant to EB613’s next hurdle: converting positive Phase 2 biomarker and bone-density data into a registrational program and eventual regulatory filing. 〔1〕 This is a capability upgrade, not a clinical or regulatory milestone. The filing does not announce new trial data, an FDA decision, a financing, or a change to the development timeline. It strengthens the board’s apparent fit for the company’s late-stage and women’s-health strategy, but any value is indirect and still has to show up through trial execution and regulatory progress. Bottom line: The board change modestly improves Entera’s development and regulatory bench as EB613 approaches Phase 3, but it does not materially de-risk the program today or change the company’s near-term milestones.**

What to watch next

EB613 Phase 3 study initiation, late 2026

Original filing on SEC EDGAR

More Entera Bio Ltd. news

Entera Bio board adds Organon R&D chief as Phase 3 nears | ENTX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.